10-Q: Apellis Pharmaceuticals Reports Q2 Loss Amid Revenue Decline, Boosted by New Approvals and Strategic Financing

Apellis Pharmaceuticals reported increased net losses and decreased product revenue for the second quarter and first half of 2025, but secured significant liquidity through a royalty buy-down agreement and gained a new FDA approval for EMPAVELI.

Summary

• Net loss for the three months ended June 30, 2025, increased to $42.151 million from $37.657 million in the prior year period.
• Net loss for the six months ended June 30, 2025, increased to $134.376 million from $104.080 million in the prior year period.
• Total revenue for Q2 2025 decreased by 11% to $178.494 million, down from $199.685 million in Q2 2024.
• Total revenue for the six months ended June 30, 2025, decreased by 7% to $345.291 million, down from $372.009 million in the same period of 2024.
• SYFOVRE net product revenue for Q2 2025 was $150.625 million, a decrease from $154.624 million in Q2 2024, primarily due to increased rebates.
• EMPAVELI net product revenue for Q2 2025 was $20.762 million, a decrease from $24.512 million in Q2 2024, attributed to increased competitive pressure from oral products.
• Research and development expenses decreased by 14% to $67.015 million in Q2 2025, largely due to lower costs in PNH, IC-MPGN & C3G, and discontinuation of ALS and CAD programs, partially offset by increased GA costs.
• Selling, general and administrative expenses increased by 2% to $131.139 million in Q2 2025, driven by higher professional fees, factoring fees, and insurance.
• Cash and cash equivalents stood at $370.036 million as of June 30, 2025, down from $411.290 million at December 31, 2024.
• The accumulated deficit reached $3.2 billion as of June 30, 2025.
• On July 1, 2025, a Royalty Buy-Down Agreement with Sobi provided an upfront payment of $275.0 million, reducing Sobi's royalty obligations by 90% subject to caps.
• EMPAVELI received FDA approval for the treatment of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) on July 28, 2025.

Sentiment

Score: 6

Explanation: While current financial performance shows increased losses and decreased revenue, the significant cash injection from the Sobi royalty buy-down and the recent FDA approval for EMPAVELI in C3G/IC-MPGN provide strong positive momentum for future growth and liquidity. Pipeline advancements also contribute positively, offsetting the immediate financial headwinds.

Positives

• EMPAVELI received FDA approval for C3G and IC-MPGN on July 28, 2025, expanding its market to an estimated 5,000 patients in the United States.
• The VALIANT study for EMPAVELI in C3G and IC-MPGN demonstrated positive effects, including a 68% reduction in proteinuria and stabilization of kidney function.
• A Royalty Buy-Down Agreement with Sobi on July 1, 2025, provided an upfront payment of $275.0 million, significantly boosting liquidity.
• Initiated a Phase 2 multi-dose trial for SYFOVRE combined with APL-3007 (siRNA) in patients with geographic atrophy (GA) in June 2025.
• Plans to initiate two pivotal clinical trials for EMPAVELI in the second half of 2025 for primary focal segmental glomerulosclerosis (FSGS) and delayed graft function (DGF), addressing rare nephrology conditions with no approved therapies.
• Commenced preclinical studies with Beam Therapeutics for a potential first-in-class FcRn gene editing treatment with one-time dosing potential.
• Royalty revenue from Sobi increased to $5.9 million in Q2 2025 from $4.4 million in Q2 2024, and to $12.0 million in 6M 2025 from $8.9 million in 6M 2024, indicating increased Aspaveli sales outside the US.

Negatives

• Net loss increased to $42.151 million for Q2 2025, up from $37.657 million in Q2 2024.
• Net loss for the six months ended June 30, 2025, increased to $134.376 million, up from $104.080 million in the same period of 2024.
• Total revenue decreased by 11% in Q2 2025 and 7% in the first six months of 2025 compared to the prior year periods.
• SYFOVRE net product revenue decreased in Q2 2025 and 6M 2025, primarily due to increased rebates.
• EMPAVELI net product revenue decreased in Q2 2025 and 6M 2025 due to increased competitive pressure from oral products.
• Licensing and other revenue significantly decreased by 65% in Q2 2025, mainly due to a $14.9 million decrease in product supplied to Sobi.
• Interest income decreased due to decreased investments.
• Interest expense increased due to the Credit Facility.
• Discontinued development of systemic pegcetacoplan for Transplant-associated Thrombotic Microangiopathy (TA-TMA) following a strategic assessment.
• The company continues to incur significant annual net operating losses and expects this trend to continue for at least the current year, excluding the Sobi Royalty Agreement proceeds.

Risks

• Ability to raise additional capital to fund operations.
• Development of new technological innovations by competitors.
• Ability to successfully complete preclinical and clinical development of product candidates and receive timely regulatory approval.
• Market acceptance of the company's products.
• Protection of proprietary technology and intellectual property.
• Impact of healthcare cost containment initiatives.
• Compliance with governmental regulations, including those of the U.S. Food and Drug Administration (FDA).
• Uncertainty regarding the nature, timing, and costs of completing clinical development for product candidates.
• Fluctuations in operating results from quarter to quarter and year to year.
• Costs and ability to obtain regulatory approvals of SYFOVRE outside of the United States.
• Costs of establishing and maintaining commercial infrastructure and manufacturing capabilities.
• Ability to maintain a productive collaborative relationship with Sobi and achieve milestone payments.
• Ability to identify additional collaborators for product candidates.
• Effect of competing technological and market developments.
• Effect of public health crises on the healthcare system and operations.
• Ability to obtain adequate reimbursement for EMPAVELI and SYFOVRE.
• Ongoing legal proceedings, including a securities class action and stockholder derivative lawsuits, which could result in significant damages or costs.

Future Outlook

The company expects to continue incurring significant commercialization expenses for EMPAVELI and SYFOVRE, along with increased research and development costs for its pipeline. It anticipates continued net operating losses for at least the current year, excluding the Sobi Royalty Agreement proceeds. The company believes its current cash, cash equivalents, and anticipated sales revenue, combined with the recent $275.0 million Sobi royalty buy-down, will be sufficient to fund operations and capital expenditures for at least the next twelve months. Future plans include initiating two pivotal clinical trials for EMPAVELI in FSGS and DGF in the second half of 2025, and continuing preclinical studies for a next-generation gene editing therapy with Beam Therapeutics.

Management Comments

• We believe SYFOVRE has the potential to be the standard of care for patients with GA, a disease that affects an estimated 1.5 million people in the United States.
• We intend to focus our commercialization efforts in the U.S. and explore international expansion in select markets, including Australia, where we received marketing approval in January 2025 for SYFOVRE.
• We believe that EMPAVELI has the potential to be a best-in-class treatment for a range of indications with high unmet needs.
• Following the FDA's approval of EMPAVELI for the treatment of C3G and IC-MPGN on July 28, 2025, we intend to commercialize EMPAVELI for these two nephrological conditions, which together, affect an estimated 5,000 people in the United States.
• We plan to initiate two pivotal clinical trials with EMPAVELI in the second half of 2025 for the treatment of primary focal segmental glomerulosclerosis, or FSGS, and delayed graft function, or DGF.
• Through our collaboration with Beam Therapeutics, Inc., we have commenced preclinical studies for a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing.
• We expect to continue to incur significant commercialization expenses related to sales, marketing, medical affairs, manufacturing, distribution and other commercial infrastructure associated with the commercialization of EMPAVELI for the treatment of PNH and other indications and the commercialization of SYFOVRE for the treatment of GA.
• We expect to continue to incur these expenses if and as we continue to develop and conduct our ongoing and planned clinical trials of pegcetacoplan and our other product candidates; initiate and continue research and preclinical and clinical development efforts for any future product candidates; seek to identify and develop additional product candidates for complement-dependent diseases; seek regulatory and marketing approvals for our product candidates that successfully complete clinical trials, if any; establish sales, marketing, distribution and other commercial infrastructure to commercialize any additional products for which we may obtain marketing approval; require the manufacture of larger quantities of product candidates for clinical development and, potentially, commercialization; maintain, expand and protect our intellectual property portfolio; hire and retain additional personnel, such as clinical, quality control, regulatory and scientific personnel; add operational, financial and management information systems and personnel, including personnel to support our product development and add equipment and physical infrastructure to support our research and development programs and commercialization.

Industry Context

Apellis Pharmaceuticals operates in the highly competitive biopharmaceutical industry, focusing on complement system inhibition. The approval of EMPAVELI for C3G and IC-MPGN positions the company to address significant unmet needs in rare nephrological conditions, potentially expanding its market share beyond PNH. The decline in EMPAVELI revenue due to oral product competition highlights the dynamic nature of the PNH market. The company's investment in next-generation therapies like SYFOVRE with APL-3007 and the gene editing collaboration with Beam Therapeutics reflects a broader industry trend towards advanced therapeutic modalities and combination therapies to enhance efficacy and patient outcomes.

Comparison to Industry Standards

• The 68% reduction in proteinuria in C3G and IC-MPGN patients treated with EMPAVELI in the VALIANT study (p < 0.0001) represents a significant clinical benefit, potentially setting a new benchmark for treatment efficacy in these rare kidney diseases, where no approved therapies currently exist.
• The stabilization of kidney function (nominal p=0.03) and reduction in C3c staining intensity observed with EMPAVELI in C3G/IC-MPGN patients are strong indicators of disease modification, which could differentiate it from symptomatic treatments or less targeted therapies in the nephrology space.
• SYFOVRE's commercialization efforts in geographic atrophy (GA) target a large patient population (estimated 1.5 million in the US), positioning it against other emerging GA treatments or off-label uses of existing retinal therapies, though specific comparative sales data or market share against competitors like Iveric Bio's Zimura (avacincaptad pegol) are not detailed in this filing.
• The company's strategy to develop a next-generation therapy combining SYFOVRE with APL-3007 (siRNA) for GA aligns with industry efforts to improve treatment durability and efficacy in chronic retinal diseases, similar to how companies like Regeneron (Eylea) and Novartis (Beovu) continuously innovate in the wet AMD space.
• The collaboration with Beam Therapeutics on a gene editing treatment for FcRn represents an entry into a cutting-edge therapeutic area, comparable to the gene therapy pipelines of companies like Sarepta Therapeutics or Spark Therapeutics, aiming for one-time dosing solutions for chronic conditions.

Corporate Governance

Legal Proceedings

• A putative class action lawsuit (Judith M. Soderberg) was filed on August 2, 2023, alleging violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5, related to alleged misrepresentations/omissions concerning SYFOVRE's clinical trials and commercial adoption risks. The amended complaint was filed on February 8, 2024. The court granted the defendants' motion to dismiss with prejudice on March 17, 2025, but the plaintiffs filed an appeal to the United States Court of Appeals for the First Circuit on April 16, 2025.
• Two putative stockholder derivative lawsuits (Patrick Campbell and Kenneth Olson) were filed on December 19, 2024, and December 30, 2024, respectively, alleging breach of fiduciary duty, unjust enrichment, waste, and violation of Section 14(a) of the Exchange Act, also related to SYFOVRE's clinical trials and commercial risks. These cases were consolidated on January 21, 2025, and stayed pending the court's ruling on the motion to dismiss in the securities class action.

Stakeholder Impact

• Shareholders: Experience increased net losses in the current period, but benefit from improved liquidity due to the Sobi Royalty Buy-Down and potential future revenue growth from new EMPAVELI indications and pipeline advancements. Ongoing legal proceedings introduce uncertainty.
• Patients (C3G/IC-MPGN): Will gain access to EMPAVELI as an approved treatment for their conditions, addressing a high unmet medical need.
• Patients (GA): May benefit from ongoing development of next-generation SYFOVRE therapies (SYFOVRE + APL-3007) aimed at improving treatment outcomes.
• Employees: The company continues to invest in research and development, and commercial infrastructure, suggesting ongoing employment opportunities, though personnel cost decreases were noted in SG&A.
• Sobi (Collaboration Partner): Benefits from a 90% reduction in royalty payment obligations under the new Royalty Buy-Down Agreement, subject to performance caps, potentially increasing their profitability from Aspaveli sales outside the US.
• Creditors (Sixth Street Lending Partners): The company's liquidity position is strengthened by the Sobi Royalty Buy-Down, and prepayment premium periods for the Credit Facility have been extended, indicating continued financial stability for debt servicing.

Next Steps

• Commercialize EMPAVELI for C3G and IC-MPGN in the United States following its FDA approval on July 28, 2025.
• Initiate two pivotal clinical trials with EMPAVELI in the second half of 2025 for primary focal segmental glomerulosclerosis (FSGS) and delayed graft function (DGF).
• Continue commercialization efforts for SYFOVRE in the U.S. and explore international expansion in select markets, including Australia.
• Continue the Phase 2 multi-dose trial for SYFOVRE combined with APL-3007 in patients with geographic atrophy.
• Continue preclinical studies for the FcRn gene editing treatment through the collaboration with Beam Therapeutics.
• Monitor the appeal process in the securities class action lawsuit following the dismissal of the amended complaint.

Key Dates

Recommendation

While the company reported increased net losses and decreased product revenue for the quarter and six-month period, which are negative indicators, these are significantly offset by the recent FDA approval of EMPAVELI for C3G and IC-MPGN, opening a new market, and the substantial $275.0 million upfront payment from the Sobi Royalty Buy-Down Agreement, which materially improves the company's liquidity position. The ongoing legal proceedings introduce some uncertainty, but the dismissal of the class action complaint (though appealed) is a positive development. The pipeline advancements, including new EMPAVELI trials and the Beam Therapeutics collaboration, offer future growth potential. Given the mixed financial performance but strong strategic and liquidity improvements, a 'Hold' recommendation is appropriate, suggesting investors monitor the commercial uptake of the new EMPAVELI indication and further pipeline progress.

Keywords

Biopharmaceutical, Complement System, C3 Inhibition, Geographic Atrophy, SYFOVRE, Pegcetacoplan, Paroxysmal Nocturnal Hemoglobinuria, EMPAVELI, C3 Glomerulopathy, IC-MPGN, Rare Diseases, Clinical Trials, FDA Approval, Royalty Agreement, Financial Results, Net Loss, Revenue, Drug Development, Ophthalmology, Nephrology